Nothing Special   »   [go: up one dir, main page]

MX2015005993A - Composiciones y metodos para el tratamiento de displasia ectodermica. - Google Patents

Composiciones y metodos para el tratamiento de displasia ectodermica.

Info

Publication number
MX2015005993A
MX2015005993A MX2015005993A MX2015005993A MX2015005993A MX 2015005993 A MX2015005993 A MX 2015005993A MX 2015005993 A MX2015005993 A MX 2015005993A MX 2015005993 A MX2015005993 A MX 2015005993A MX 2015005993 A MX2015005993 A MX 2015005993A
Authority
MX
Mexico
Prior art keywords
compositions
methods
treatment
ectodermal dysplasia
administration
Prior art date
Application number
MX2015005993A
Other languages
English (en)
Inventor
Kenneth M Huttner
Neil Kirby
Pascal Schneider
Olivier Gaide
Original Assignee
Edimer Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Edimer Pharmaceuticals Inc filed Critical Edimer Pharmaceuticals Inc
Publication of MX2015005993A publication Critical patent/MX2015005993A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se relaciona con composiciones farmacéuticas y métodos para el tratamiento de displasias ectodérmicas vía la administración de agonistas EDA, en particular EDI200. El uso de las composiciones y métodos descritos permite regímenes de dosificación terapéutica y administración en pacientes humanos para corregir o altera fenotipos anormales asociados con trastornos genéticos, en particular, XLHED.
MX2015005993A 2012-11-14 2013-11-13 Composiciones y metodos para el tratamiento de displasia ectodermica. MX2015005993A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261726252P 2012-11-14 2012-11-14
US201361825227P 2013-05-20 2013-05-20
PCT/US2013/069799 WO2014078353A1 (en) 2012-11-14 2013-11-13 Compositions and methods for the treatment of ectodermal dysplasia

Publications (1)

Publication Number Publication Date
MX2015005993A true MX2015005993A (es) 2015-12-09

Family

ID=50731641

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005993A MX2015005993A (es) 2012-11-14 2013-11-13 Composiciones y metodos para el tratamiento de displasia ectodermica.

Country Status (14)

Country Link
US (1) US20160272694A1 (es)
EP (1) EP2920318A4 (es)
JP (1) JP2015536344A (es)
KR (1) KR20150099720A (es)
AR (1) AR093476A1 (es)
AU (1) AU2013344973B2 (es)
BR (1) BR112015011099A2 (es)
CA (1) CA2891386A1 (es)
IL (1) IL238602A0 (es)
MX (1) MX2015005993A (es)
RU (1) RU2015117995A (es)
SG (1) SG11201503777YA (es)
TW (1) TW201438730A (es)
WO (1) WO2014078353A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3060245B1 (en) * 2013-10-22 2020-02-26 EspoirXLHED Sàrl Intra-amniotic administration of proteins for the treatment of ectodermal dysplasias
JP2020154179A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
JP2020154178A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
JP2020154180A (ja) * 2019-03-20 2020-09-24 ヤフー株式会社 情報処理装置、情報処理方法および情報処理プログラム
CN114145452B (zh) * 2021-12-10 2022-11-01 青岛圣桐营养食品有限公司 特殊医学用途全营养配方食品

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6506569B1 (en) * 1997-05-30 2003-01-14 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR10
EP1516054B1 (de) * 2002-02-10 2009-12-02 Topotarget Switzerland SA Fusionkonstrukte, enthaltend aktive abschnitte von tnf-liganden
JP5955382B2 (ja) * 2011-05-13 2016-07-20 エディマー ファーマシューティカルズ インコーポレイテッドＥｄｉｍｅｒ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Ｘｌｈｅｄ表現型を変更するための組成物および方法

Also Published As

Publication number Publication date
CA2891386A1 (en) 2014-05-22
AU2013344973A1 (en) 2015-05-14
BR112015011099A2 (pt) 2017-08-22
US20160272694A1 (en) 2016-09-22
WO2014078353A1 (en) 2014-05-22
EP2920318A4 (en) 2016-04-13
SG11201503777YA (en) 2015-06-29
TW201438730A (zh) 2014-10-16
EP2920318A1 (en) 2015-09-23
RU2015117995A (ru) 2017-01-10
AU2013344973B2 (en) 2016-10-06
KR20150099720A (ko) 2015-09-01
JP2015536344A (ja) 2015-12-21
IL238602A0 (en) 2015-06-30
AR093476A1 (es) 2015-06-10

Similar Documents

Publication Publication Date Title
NZ630805A (en) Pharmaceutical combinations comprising a thionucleotide analog
PH12015500940A1 (en) Bruton`s tyrosine kinase inhibitors
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
PH12021551189A1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
PH12016500575A1 (en) Inhibitors of bruton`s tyrosine kinase
PH12014502058A1 (en) Pharmaceutical composition comprising empagliflozin and antiobesity drug
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PH12015501067A1 (en) Pyrrolopyrimidine compounds as kinase inhibitors
MY174727A (en) Stable, protracted glp-1/glucagon receptor co-agonists for medical use
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX370953B (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
MX352824B (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación.
PH12016500863A1 (en) Tetracyclic autotaxin inhibitors
MX2015011905A (es) Uso de levocetirizina y montelukast en el tratamiento de la vasculitis.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2015005993A (es) Composiciones y metodos para el tratamiento de displasia ectodermica.
MX2016008027A (es) Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
GB201115977D0 (en) Neurodevelopmental disorders
TW201613926A (en) Inhibitors of bruton's tyrosine kinase
BR112015002384A8 (pt) combinações farmacêuticas compreendendo um inibidor de b-raf, um inibidor de egfr e, opcionalmente, um inibidor de pi3k-alfa, e seus usos".